---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-089839"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-08-03T21:00:36+00:00"
generated_at: "2026-08-03T21:02:12.147219+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Supernus and Indivior announce all-stock merger of equals to create CNS-focused biopharma company

## Summary
- All-stock merger of equals between Supernus and Indivior; combined company to have four established CNS/behavioral health franchises.
- Jack Khattar (Supernus CEO) to serve as CEO of combined company; transaction expected to close in Q4 2026.
- Combined portfolio includes SUBLOCADE (opioid use disorder), Qelbree (ADHD), Zurzuvae (postpartum depression), Onapgo and GOCOVRI (Parkinson's).
- Merger intended to create financial strength and flexibility for business development; integration planning to be structured.

## SEC filing metadata
- accession: 0001104659-26-089839
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-08-03T21:00:36+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000110465926089839/0001104659-26-089839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000110465926089839/tm2622009d7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-089839
- JSON: https://secwatch.observer/filing/0001104659-26-089839.json
- Plain text: https://secwatch.observer/filing/0001104659-26-089839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.